- Faron Pharmaceuticals said it would continue its study on its treatment for acute respiratory distress syndrome after a clinical trial indicated it was too early to determine the efficacy of the treatment.

The ratio of the Faron’s Traumakine treatment arm versus placebo was two to one and mortality was assessed for a period of 30 days after surgery, during the INFORAAA trial.

A total of 35 patients were included in the interim read out, 25 of which were treated with Traumakine and 10 of which received placebo, the company said.

The interim read out was hindered somewhat due to the magnitude of steroid used in this patient population, but the company said it had observed a trend toward reduction of mortality in the Traumakine-treated patients who did not receive corticosteroids.

‘Mortality in various groups varied from 15-20%, except in those patients without induced CD73 concentrations - mortality in that group was high with 6 out of 7 (85.7%) not surviving,’ the company added.

‘INFORAAA interim data is very important to us as it again shows the protective effects of CD73 activation without the presence of steroids. It is still too early to estimate the efficacy of Traumakine in this setting because of the limited number of evaluable patients without concomitant steroids, however the interim analysis supports the continuation of the study according to current power,’ said Dr Markku Jalkanen, Chief Executive Officer of Faron.

At 8:46am: [LON:FARN] Faron Pharmaceuticals share price was -20p at 114.5p

Story provided by